Research article

Open Access

Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma

Dirk Vordermark^{*1}, Oliver Kölbl¹, Klemens Ruprecht², Giles H Vince³, Klaus Bratengeier¹ and Michael Flentje¹

Address: ¹Dept. of Radiation Oncology, University of Würzburg, Germany, ²Dept. of Neurology, University of Würzburg, Germany and ³Dept. of Neurosurgery, University of Würzburg, Germany

Email: Dirk Vordermark* - vordermark_d@klinik.uni-wuerzburg.de; Oliver Kölbl - oliver.koelbl@klinik.uni-regensburg.de; Klemens Ruprecht - klemens.ruprecht@mail.uni-wuerzburg.de; Giles H Vince - gvince@gmx.de; Klaus Bratengeier - Bratengeie_K@klinik.uni-wuerzburg.de; Michael Flentje - flentje_M@klinik.uni-wuerzburg.de

* Corresponding author

Published: 30 May 2005

BMC Cancer 2005, 5:55 doi:10.1186/1471-2407-5-55

This article is available from: http://www.biomedcentral.com/1471-2407/5/55

© 2005 Vordermark et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<u>http://creativecommons.org/licenses/by/2.0</u>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: 19 February 2005 Accepted: 30 May 2005

Abstract

Background: Hypofractionated stereotactic radiotherapy (HFSRT) is one salvage treatment option in previously irradiated patients with recurrent malignant glioma. We analyzed the results of HFSRT and prognostic factors in a single-institution series.

Methods: Between 1997 and 2003, 19 patients with recurrent malignant glioma (14 glioblastoma on most recent histology, 5 anaplastic astrocytoma) were treated with HFSRT. The median interval from post-operative radiotherapy to HFSRT was 19 (range 3–116) months, the median daily single dose 5 (4–10) Gy, the median total dose 30 (20–30) Gy and the median planning target volume 15 (4–70) ml.

Results: The median overall survival (OS) was 9.3 (1.9-77.6+) months from the time of HFSRT, 15.4 months for grade III and 7.9 months for grade IV tumors (p = 0.029, log-rank test). Two patients were alive at 34.6 and 77.6 months. OS was longer after a total dose of 30 Gy (11.1 months) than after total doses of <30 Gy (7.4 months; p = 0.051). Of five (26%) reoperations, none was performed for presumed or histologically predominant radiation necrosis. Median time to tumor progression after HFSRT on imaging was 4.9 months (1.3 to 37.3) months.

Conclusion: HFSRT with conservative total doses of no more than 30 Gy is safe and leads to similar OS times as more aggressive treatment schemes. In individual patients, HFSRT in combination with other salvage treatment modalities, was associated with long-term survival.

Background

Despite intensive multi-modality treatment including tumor resection, post-operative radiotherapy and frequently adjuvant chemotherapy, the prognosis of malignant glioma continues to be poor. Local recurrence, occuring almost exclusively inside the high-dose volume of post-operative radiotherapy [1], represents a major therapeutic challenge. Re-irradiation as a salvage treatment option is limited by the radiation tolerance of surrounding normal brain tissue. In recent years, single-dose radiosurgery, normofractionated and hypofractionated stereotactic radiotherapy have been investigated as a

median age (range) at time of HFSRT	50 years	(11–74 years)	
male / female	8 (42%)/11(58%)		
median Karnofsky performance score at time of HFSRT (range)	90	(60–90)	
initial histology			
astrocytoma II°	3 (16%)		
pure anaplastic astrocytoma III°	4 (21%)		
anaplastic oligoastrocytoma or oligodendroglioma III°	3 (16%)		
glioblastoma multiforme IV°	9 (47%)		
most recent histology before HFSRT			
anaplastic astrocytoma III°	5 (26%)		
glioblastoma multiforme IV°	14 (74%)		
initial surgical procedure			
resection	15 (79%)		
biopsy	4 (21%)		
post-operative radiotherapy			
1.8–2.0 Gy daily (total dose 54 to 61 Gy)	12 (63%)		
3 Gy daily (total dose 45 Gy)	2 (11%)		
2 × 1.8 Gy daily (total dose 54 Gy)	5 (26%)		
salvage surgery before HFSRT	12 (63%)		
adjuvant or salvage chemotherapy before HFSRT			
nimustine / teniposide	12 (63%)		
temozolomide	5 (26%)		
other	l (5%)		
median interval post-OP radiotherapy to HFSRT (range)	19 months	(3–116 months	

Table I: Clinical characteristics of n = 19 consecutive patients treated with hypofractionated stereotactic radiotherapy (HFSRT) for recurrent malignant glioma.

single modality or in combination with chemotherapy [2-8]. Re-irradiation appeared to be associated with acceptable toxicity when certain treatment volume and dose limits were respected. Median survival in these series was between 7 and 13 months from the time of salvage radio-therapy suggesting a therapeutic benefit in selected patient groups.

Since published data on hypofractionated stereotactic radiotherapy as a sole modality in recurrent malignant glioma are limited [4,5,8], we now analyzed the results of such treatment in 19 consecutive patients treated at a single institution.

Methods

Patients


Between 1997 and 2003, 19 patients were treated with hypofractionated stereotactic radiotherapy (HFSRT) for recurrent malignant glioma at the University of Würzburg, Germany. The patient characteristics are summarized in Table 1. All patients had received previous involved-field radiotherapy with 45 to 61 Gy and 94% of patients had been pretreated with chemotherapy, most often nimustine (ACNU) and teniposide, a combination protocol favored by the Neuro-Oncology Working Group of the German Cancer Society [9].

Treatment technique

HFSRT was performed non-invasively using a commercially available relocatable mask system as previously described [10]. For planning CT, 3 mm scans of the brain were obtained after administration of an i. v. contrast agent. Treatment planning was performed using Helax TMS (Nucletron, Veenendal, Netherlands) software. For planning target volume (PTV) definition, a margin of 1 to 3 mm around the contrast-enhancing volume was used. Depending on the shape of the PTV, treatment plans were created containing multiple non-coplanar arcs, multiple non-coplanar fixed fields or combinations of both. The treatment plans were normalized to 100% at the isocenter

Median planning target volume (range)	I5 ml	(4–70 ml)
Median prescription isodose (range)	80%	(70–90%)
Median single dose (range)	5 Gy	(4–10 Gy)
Median total dose (range)	30 Gy	(20–30 Gy)
Fractionation schedules		
5 × 4 Gy	2 (11%)	
4 × 5 Gy	5 (26%)	
6 × 5 Gy	6 (32%)	
5 × 6 Gy	5 (26%)	
2 × 10 Gy	I (5%)	
HFSRT technique		
multiple non-coplanar arcs	5 (26%)	
multiple non-coplanar fixed fields	11 (58%)	
combination arcs / fixed fields	3 (16%)	
median field no. (range)	5	(3–8)

Table 2: Treatment details of hypofractionated stereotactic
radiotherapy (HFSRT) in n = 19 consecutive patients with
recurrent malignant glioma.





Overall survival of n = 19 patients with recurrent malignant glioma treated with hypofractionated stereotactic radiotherapy (HFSRT), from the time of re-irradiation.

and prescribed to a median isodose of 80% (range 70 to 90%), enclosing the PTV. Details of treatment planning and dose prescription are given in Table 2.

Immediately before the first treatment session, CT simulation was performed as described [10]. Briefly, the isocenter position was verified with regard to bony and parenchymal landmarks and to the contrast enhancing tumor and positioning errors were corrected after attaching the mask system to the treatment table. Treatment was delivered from a Philips SL 75/20 or Siemens Primus linear accelerator (6 MV or 8 MV photons, respectively) equipped with a manual micro-multileaf collimator. Subsequent CT simulations were performed at the discretion of the treating physician depending on the setup error determined at time of the first fraction. HFSRT treatment was performed five days per week. During the HFSRT series, patients were maintained on their previous corticosteroid dose or corticosteroids were started. Daily doses ranged between 32 mg of prednisolone and 40 mg of dexamethasone.

Statistics

The main endpoint of this study was overall survival (OS) from the time of HFSRT. Kaplan-Meier survival curves were calculated for these intervals considering death as an event and patients alive at last follow-up as censored. Subgroups were compared using the log-rank test. Statistical analysis was performed with Statistica 6.1 software (Tulsa, OK, USA). Overall survival from initial diagnosis and time to tumor progression were considered as secondary endpoints. For the analysis of time to recurrence, neuroradiological diagnoses of follow-up CT and MRI scans were used. Imaging was routinely reviewed by an interdisciplinary tumor board which based its recommendations on these studies.

Results

HFSRT was well tolerated and no acute neurotoxicity or deterioration in the general health status was observed. Five of 19 patients were reoperated after HFSRT. In three of these, resection was performed for tumor progression on imaging. Histology showed tumor only in two of these cases and predominant tumor with necrosis in one case. In two patients, Ommaya reservoirs were implanted. Thirteen patients received further chemotherapy after HFSRT. Temozolomide was used in six patients, nimustine / teniposide in four and other multi-agent protocols in three.

For the whole group of n = 19 patients with recurrent malignant glioma, the median overall survival from the time of HFSRT was 9.3 months (range 1.9 to 77.6+ months; Fig. 1). At the time of analysis, two patients were alive at 34.6 months and 77.6 months. One-year and two-year survival rates were 26% and 16%, respectively. Overall survival from time of HFSRT for subgroups is shown in Table 3.

WHO grading, both that determined at initial diagnosis of glioma and the most recent before HFSRT, had a significant impact on survival. Patients with a most recent histopathology of a grade III glioma had a median overall

	n	median (range) overall survival (months)	Р
WHO grade (initial histopathology)			
ll or lll	10	13.5 (1.9–77.6)	0.036
IV	9	7.4 (4.2–10.8)	
WHO grade (most recent before HFSRT)			
111	5	15.4 (1.9–77.6)	0.029
IV	14	7.9 (4.2–38.8)	
initial surgical procedure			
biopsy	15	9.3 (4.2–77.6)	0.89
resection	4	9.2 (1.9–34.6)	
chemotherapy before HFSRT			
yes	13	9.3 (1.9–77.6)	0.76
no	6	8.9 (7.3–15.4)	
reoperation before HFSRT			
yes	12	8.4 (1.9–77.6)	0.93
no	7	9.3 (5.6–34.6)	
age at time of HFSRT			
< 50 years	11	11.9 (1.9–77.6)	0.14
> 50 years	8	8.9 (5.0–11.1)	
Karnofsky performance score at time of HFSRT			
≥ 90	14	7.9 (4.2–77.6)	0.80
< 90	5	11.9 (1.9–15.4)	
planning target volume (ml)			
< 15 ml	9	9.3 (5.2–38.8)	0.59
> 15 ml	10	7.4 (1.9–77.6)	
interval first RT series to HFSRT			
> 20 months	9	7.4 (1.9–77.6)	0.90
< 20 months	10	9.3 (5.6–38.8)	
total HFSRT dose			
30 Gy		. (.9–77.6)	0.051
< 30 Gy	8	7.4 (4.2–11.9)	
chemotherapy after HFSRT			
yes	13	9.3 (1.9–77.6)	0.27
no	6	8.9 (4.2–11.1)	

Table 3: Median overall survival from the time of hypofractionated stereotactic radiotherapy (HFSRT) in subgroups of patients with recurrent malignant glioma.

survival from the time of HFSRT of 15.4 (1.9 to 77.6) months, those with grade IV tumors of 7.9 (4.2 to 38.8) months (p = 0.029, log-rank test; Fig. 2). A trend toward a beneficial effect of higher total doses (30 Gy vs. <30 Gy) on overall survival was observed (p = 0.051; Table 3, Fig. 3). Median overall survival from the first histological diagnosis of glioma (of any grade) was 40.8 months (12.9 to 135 months). Respective median overall survival times from first diagnosis by initial histological grade were

134.7 (64.5 to 135) months for WHO grade II, 57 (30.8 to 119.4+) months for grade III and 26 (12.9 to 40.8) months for grade IV tumors.

Information on follow-up imaging was available in 15 patients. Tumor progression was first diagnosed on MRI in 11 cases and on CT in four cases. The median interval between HFSRT and documented tumor progression was 4.9 months (1.3 to 37.3 months) in the overall group and





Figure 2

Overall survival from the time of re-irradiation of n = 19 patients with recurrent malignant glioma treated with hypofractionated stereotactic radiotherapy (HFSRT), by WHO grade (most recent histopathology before HFSRT).





Overall survival from the time of re-irradiation of n = 19 patients with recurrent malignant glioma treated with hypofractionated stereotactic radiotherapy (HFSRT), by total dose.

7.6 months (3.9 to 37.3 months) and 4.6 months (1.3 to 29.5 months) in the subgroups with a most recent histology of grade III astrocytoma and glioblastoma, respectively.

Survival times from initial diagnosis for the two living patients were 49.7 and 119.4 months. The patient alive at 119.4 months (77.6 months from HFSRT) is a child first treated with HFSRT at the age of eleven for a fourth recurrence of an anaplastic astrocytoma after multiple resections, fractionated radiotherapy and intensive multiagent chemotherapy. After further adjuvant chemotherapy, this patient recurred 37 months after HFSRT and has since been treated with another resection, a second series of HFSRT (49 months after the first HFSRT) to a volume adjacent to the initial HFSRT region (7 × 5 Gy, 80% isodose) and implantation of BCNU polymers. The most recent MRI in this patient showed no evidence of tumor recurrence. This patient was the only pediatric case included in the present analysis. The patient alive at 49.7 months from initial diagnosis (34.6 months from HFSRT) was first treated for anaplastic astrocytoma at 34 years with biopsy, involved-field radiotherapy and multi-agent chemotherapy. Twelve months after the first radiotherapy series, HFSRT and sequential temozolomide were given for tumor recurrence.

Discussion

Local recurrence of malignant glioma pretreated with resection, post-operative radiotherapy and frequently

with adjuvant chemotherapy is a common problem in clinical practice. Reoperation, re-irradiation and systemic or intratumoral chemotherapy are among the therapeutic options available in this situation. Only the implantation of BCNU polymers at the time of reoperation is supported by randomized trial data, having been shown to be superior to re-resection alone [11]. The benefit of other treatments needs to be evaluated based on phase II data and retrospective analyses which both are prone to bias by patient selection for salvage treatment. A recent large retrospective investigation analyzed the benefit of salvage treatment in patients with glioblastoma multiforme [12]. The authors found that the first, mostly chemotherapeutic, reintervention in this patient group was associated with a doubling in median overall survival from 26 to 61.5 weeks, although selection effects in this series can not be excluded.

Prolongation of survival in recurrent malignant glioma has not been convincingly shown for either re-resection or re-irradiation by interstitial brachytherapy, single-dose radiosurgery or fractionated radiotherapy [13]. Hypofractionated stereotactic radiotherapy (HFSRT) has been proposed as a combination of high-precision treatment with small margins and maximum sparing of normal brain tissue, non-invasive technique and short treatment duration using single fraction doses of 3 Gy to 9 Gy (Table 4).

authors	patient number	single dose (Gy)	total dose (Gy)	median tumor volume (ml)	chemo- therapy	overall survival (median)	surgery for toxicity	prognostic factors	comment
Shepherd et al., 1997 [4]	29 ("high- grade astrocy- toma")	5 (daily)	20–50	24 (3–93)		10.7 months	6%	initial low- grade histology associated with longer survival	36% steroid dependent toxicity (increased risk >40 Gy)
Glass et al., 1997 [6]	20 (7 grade III, 13 grade IV)	3.5–6 (twice / week)	35–42	14 (2–122)	cisplatin 40 mg/ m ² weekly	12.7 months	15% pre- dominant necrosis on re-operation		40% treated within 10 weeks of first RT series for ("potential") progression
Hudes et al., 1999 [5]	19 (glio- blastoma)	3–3.5 (daily)	24–35	13 (1–48)		10.5 months	0%	"minor response" on imaging associated with ≥30 Gy and ≤20 ml	recurrent or persistent tumors treated, median interval between completion of RT and HFSRT only 3.1 months
Lederman et al., 2000 [7]	88 (glio- blastoma)	4–9 (weekly)	18–36	32.7 (2–150)	paclitaxel 120 mg/m² (median) weekly	7 months	8% necrosis only at re- operation	volume ≥30 ml associated with longer survival	median time from diagnosis to HFSRT only 6.5 months
Voynov et al., 2002 [8]	10 (5 WHO grade III, 5 grade IV)	5	30	34.7		10.1 months	?		stereotactic intensity- modulated radiotherapy (IMRT) used
present series	19 (5 WHO grade III, 14 grade IV)	4–10 (daily)	20–30	15 (4–70)		9.3 months	0%	WHO grade IV and <30 Gy associated with short survival	median interval post-OP RT to HFSRT 19 months

Table 4: Overview of published results on hypofractionated stereotactic radiotherapy (HFSRT) in patients with recurrent malignant glioma (RT: radiotherapy).

In the present single-institution series of patients with recurrent malignant glioma, median survival times from the time of HFSRT of 9.3 months (most recent histology grade III 15.4 months, grade IV 7.9 months) were achieved. In published series of HFSRT, applied either as a single modality or in combination with chemotherapy, median overall survival ranged between 7 and 12.7 months (Table 4). Comparability between these series is limited by differences in patient selection and treatment concept. The median total dose of 30 Gy in 5-Gy fractions in the present series is close to the limit of 35 Gy which is thought to be applicable in pre-irradiated patients with acceptable toxicity [4]. However, a total dose of 20 Gy in 4-Gy or 5-Gy fractions, as used in about one third of patients, may be regarded as too low based on recent literature data [4]. Indeed, a trend toward longer survival with total doses of at least 30 Gy was observed (Table 3, Fig. 1C). The finding that no patient in the present series had to be reoperated for symptomatic radiation necrosis also suggests that the dose schedules prescribed were rather conservative. Other potential prognostic factors such as age, Karnofsky performance score or tumor size (planning target volume) were not significant predictors of survival

in the present series, possibly due to the limited patient number.

It must be noted that in many patients HFSRT was one element of salvage therapy and further chemotherapy or surgical interventions were performed in 68% and 26% of patients, respectively. In the patients with available imaging information, the median time from HFSRT to tumor progression was approximately five months which may be regarded as an approximation of the lifetime gained by HFSRT in these highly selected patients. In the patient with the longest survival time of 77.6+ months after reirradiation, a second HFSRT series was performed as well as multiple other treatments, highlighting the benefit of aggressive multi-modality treatment in individual patients. The longest survival time in glioblastoma was 38.8 months from HFSRT, indicating that even in grade IV tumors single patients may survive much longer than expected.

Data from the present series and published reports suggest that efficacy and toxicity are favorable compared to singledose radiosurgery and the invasive modality of interstitial brachytherapy. While radiosurgery resulted in median overall survival times of 26 to 50 weeks and reoperation rates of 0 to 22%, median overall survival of 47 weeks and reoperation in 41 to 44% (with about 5% of patients showing radionecrosis only) were reported for interstitial brachytherapy [13]. In a recent review of re-irradiation, HFSRT was favored as radiotherapy modality and the following criteria for the application of HFSRT were recommended [14]: good general status (WHO 0–1), at least one year disease-free interval, initial grade II or III histology and maximal tumor diameter 3 cm.

While such criteria may identify patients with the greatest benefit from HFSRT, salvage treatment decisions in recurrent malignant glioma will remain highly individualized. Given the low toxicity of the method, HFSRT may be offered to patients in good general condition with tumor recurrences of limited volume.

Conclusion

HFSRT with moderate total doses of no more than 30 Gy is safe and leads to similar OS times as more aggressive treatment schemes. In individual patients, HFSRT in combination with other salvage treatment modalities, can be associated with long-term survival.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

DV designed the analysis, reviewed patient data, performed statistical analysis and drafted the manuscript.

OK treated the patients, reviewed patient data and revised the manuscript.

KR treated the patients, reviewed patient data and revised the manuscript.

GHV treated the patients, reviewed patient data and revised the manuscript.

KB performed radiotherapy planning for the patients analyzed, reviewed radiotherapy details and revised the manuscript.

MF treated the patients, reviewed patient data and revised the manuscript.

References

- Oppitz U, Maessen D, Zunterer H, Richter S, Flentje M: 3-D recurrence patterns of glioblastomas after CT-planned postoperative irradiation. *Radiother Oncol* 1999, 53:53-57.
- Cho KH, Hall WA, Gerbi BJ, Higgins PD, McGuire WA, Clark HB: Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys 1999, 45:1133-1141.

- 3. van Kampen M, Engenhart-Cabilic R, Debus J, Fuß M, Rhein B, Wannenmacher M: **The value of radiosurgery for recurrent glioblastoma multiforme (German).** The Heidelberg experience and review of the literature. Strahlenther Onkol 1998, **174**:19-24.
- Shepherd SF, Laing RW, Cosgrove VP, Warrington AP, Hines F, Ashley SE, Brada M: Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys 1997, 37:393-398.
- Hudes RS, Corn BW, Werner-Wasik M, Andrews D, Rosenstock J, Thoron L, Downes B, Curran WJ: A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys 1999, 43:291-298.
- Glass J, Silverman CL, Axelrod R, Corn BW, Andrews DW: Fractionated stereotactic radiotherapy with cis-platinum radiosensitization in the treatment of recurrent, progressive or persistent malignant astrocytoma. Am J Clin Oncol 1997, 20:226-229.
- Lederman G, Wronski M, Arbit E, Odaimi M, Wertheim S, Lombardi E, Wrzolek M: Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol 2000, 23:155-159.
- Voynov G, Kaufman S, Hong T, Pinkerton A, Simon R, Dowsett R: Treatment of recurrent malignant gliomas with stereotactic intensity modulated radiation therapy. Am J Clin Oncol 2002, 25:606-611.
- Weller M, Müller B, Koch R, Bamberg M, Krauseneck P, Neuro-Oncology Working Group of the German Cancer Society: Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol 2003, 21:3276-3284.
- 10. Willner J, Flentje M, Bratengeier K: CT-simulation in stereotactic brain radiotherapy – analysis of isocenter reproducibility with mask fixation. *Radiother Oncol* 1997, **45**:83-88.
- Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. *Lancet* 1995, 345:1008-1012.
- Hau P, Baumgart U, Pfeifer K, Bock A, Jauch T, Dietrich J, Fabel K, Grauer O, Wismeth C, Klinkhammer-Schalke, Allgäuer M, Schuierer G, Koch H, Schlaier J, Ulrich W, Brawanski A, Bogdahn U, Steinbrecher A: Salvage Therapy in patients with glioblastoma. Is there any benefit? *Cancer* 2003, 98:2678-86.
- Nieder C, Grosu AL, Molls M: A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev 2000, 26:397-409.
- Dhermain F, de Crevoisier R, Parker F, Cioloca C, Kaliski A, Beaudre A, Lefkopoulos D, Armand JP, Haie-Meder C: Role of radiotherapy in recurrent gliomas [French]. Bull Cancer 2004, 91:883-889.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2407/5/55/prepub